Annual Meeting Highlights of ASCO 2018 in Pancreatic Cancer


Preliminary Result from the “Know Your Tumor” Program
Emanuel F. Petricoin III, PhD

Begin


Novel Approaches for Locally Advanced and Metastatic Pancreatic Cancer
Vincent Picozzi, Jr., MD, MMM

Begin


The Current State of Pancreatic Cancer: One Major Healthcare System’s Approach to Standardized Care Pathways in the Community for the Treatment of Pancreatic Cancer
Federico A. Sanchez, MD

Begin


Predicting Survival for (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (MPDAC) previously treated with gemcitabine-based therapy
Andrea Wang-Gillam, MD, PhD

Begin


Combination Therapy in Metastatic Pancreatic Cancer
J. Randolph Hecht, MD

Begin


BRCA1/2 Screening and Treatment in Metastatic Pancreatic Cancer
Eileen M. O’Reilly, MD

Begin


Review of two late-breaking trials: mFOLFIRINOX vs gemcitabine in resected pancreatic cancer, and preoperative chemoradiation vs immediate surgery for resectable pancreatic cancer
Andrea Wang-Gillam, MD, PhD

Begin

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Ipsen, and Merck & Co., Inc.